Shots:
Philip spoke about plaque psoriasis, symptoms, prognosis, and treatment options available. He also discussed different ongoing patient support programs by Dermavant
Anna talked about the approval of Dermavant’s lead topical treatment in plaque psoriasis, its clinical studies & results
The interview summarizes Dermavant’s aim to develop innovative therapeutics in immuno-dermatology to address the high…
In an interview with PharmaShots, Philip Brown, Chief Medical Officer at Dermavant share his views on the data of Tapinarof in the P-III (PSOARING 3) study for the treatment of Plaque Psoriasis & highlights new patient satisfaction data
Shots:
The P-III (PSOARING 3) extension study evaluates tapinarof (1%, qd) in adult patients with PsO for ~40wks. & a 4wks. safety follow-up period
The…

